DISCOVERY
Piramal Discovery Solutions offers a comprehensive range of Contract Research Services from our state-of-the-art research centre in India to support drug discovery activities
Synthetic Chemistry
Piramal has been offering from mg to gm scale discovery chemistries to its customers from North America, Europe and Asia
In-vitro Biology Services
Piramal’s in vitro Biology is designed to provide best in class support to our clients to enable their preclinical drug discovery.
In-vitro ADME Services
Piramal's in-vitro labs provide ADME services for faster and improved decision making for our Chemistry clients
Route Scouting
Assisting our partners in discovering and developing efficient and cost effective routes
Non-GMP Kilo lab
Piramal’s fully-equipped kilo-lab allows for rapid development of scalable and robust chemical processes using advanced process methodologies
Analytical Support Services
The chemists at Piramal are supported by a specialist & fully dedicated analytical team which operates 24/7 with suites containing advanced analytical equipment

A sneak peek into our facility

DEVELOPMENT
Piramal offers clinical development services from Phase I to Phase III for various dosage form such as Oral solids, liquids, creams, ointments, and sterile injectable
Process R&D services
Process development for small molecule intermediates, APIs and HPAPIs
Pre-Formulation Studies
Expert approach ensures quality of drugs from discovery to commercial supply
Pharmaceutical Drug Development Services
Pharmaceutical Development of oral solids, liquids, creams, ointments, and sterile injectable.
Analytical Support Services
Range of services, including method development, stability studies, validation and transfer
Regulatory Services
Expert clinical & regulatory support across all phases of drug development programs
Clinical Trial Services
Clinical Trial Manufacturing, Packaging and Supply Services using our global network

A sneak peek into our facility

MANUFACTURING
Piramal offers contract manufacturing for API, HPAPI and a wide variety of dosage forms. Our global manufacturing sites located across North America, Europe and India offer the highest standards of quality and service to the customers
API Manufacturing
We provide the manufacture and supply of Active Pharmaceutical Ingredients (APIs) on an integrated manufacturing model across North America, Europe and Asia
HPAPI
Piramal Pharma Solutions offers the development and manufacturing of High Potency API services from its Riverview facility
Finished Dosage Manufacturing
Lifecycle Management
With very small quantities of active pharmaceutical ingredients (API) or drug-able candidate molecules

A sneak peek into our facility

ANTIBODY DRUG CONJUGATION
Piramal is the global leader in delivering customer-centric solutions in the field of Antibody Drug Conjugates (ADCs) and other bioconjugates to global biopharmaceutical companies
Proof-Of-Concept Studies
Piramal offers a fast-track early stage development service for your ADC programmes. Whether you are selecting your candidate mAb, linker or toxin
Process Development and Scale Up
Piramal offers ADC process development and scale-up through Tox manufacture and into GMP manufacture
ADC Manufacturing
World-leading multi-product facility for clinical and commercial manufacturing of antibody drug conjugates (ADCs)
ADC Fill/Finish
Piramal offers aseptic filling of ADC drug product through our FDA-inspected state-of- the-art manufacturing facility in Lexington, KY
Analytical Development Services
Analytical development team covers a wide range of analytical methods from small molecule analysis through to cell killing assays and ELISA development

A sneak peek into our facility

GENERIC APIs
Piramal’s Generic API division offers an indigenous basket of off-patent APIs for global markets. With the declining pipeline of new drugs in the pharmaceutical industry, our customers are looking for off-patent APIs with competitive cost and quality
Mumbai, India
We have an experienced team of over 28 scientists including 8 Ph.D.’s dedicated to innovation in new product development, cost optimization, and novel route scouting projects
Generic API Products

A sneak peek into our facility

COVID-19

Dear Partners,

Necessitated by the unprecedented situation created by Covid-19, several industry events and tradeshows across the world have been postponed or stand cancelled. While we were looking forward to meet you, we at Piramal Pharma Solutions have had to take several precautionary measures to protect both our employees and customers, worldwide.

As we move forward in these extraordinary times, we want to assure you that that we are operational by taking the right safety measures and abundant precautions to ensure that we continue to support you and your patients.

While all of us are working remotely for now, you can schedule a discussion with us and we would be glad to help ensure you meet your pharmaceutical development and supply needs and thereby, your clinical and commercial timelines.

Please feel free to reach out to us at:
Stuart.Needleman@piramal.com

Our best wishes to colleagues, friends and family.

Best Regards,
Piramal Pharma Solutions

PiramalPharma Solutions Logo
2022 DC Chairs Statement
25 Aug 2023
READ MORE
2022 DC Implementation Statement
25 Aug 2023
READ MORE
2022 DB Implementation Statement
25 Aug 2023
READ MORE
Piramal Healthcare UK Pension Fund - Statement of Investment Principles
05 Jul 2022
READ MORE
2021 DC Chairs Statement
17 Jun 2022
READ MORE
2021 DB Implementation Statement
17 Jun 2022
READ MORE
2021 DC Implementation Statement
17 Jun 2022
READ MORE
Piramal Healthcare UK Pension Fund – Statement of Investment Principles August 2021
13 Oct 2021
READ MORE
2020 DC Chairs Statement July 2021
22 Jul 2021
READ MORE
2020 DB Implementation Statement July 2021
22 Jul 2021
READ MORE
2020 DC Implementation Statement July 2021
22 Jul 2021
READ MORE
2019 DC Chairs Statement June 2020
18 Jun 2020
READ MORE
2018 DC Chairs Statement Feb 2020
01 Feb 2020
READ MORE
2017 DC Chairs Statement June 2018
01 Jun 2018
READ MORE
2016 DC Chairs Statement June 2017
01 Jun 2017
READ MORE
2015 DC Chairs Statement June 2016
01 Jun 2016
READ MORE